The biopharmaceutical firm Cytokinetics (CYTK) develops muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised. My cardiologist probably understands how their treatments work but not me. I will check out the charts instead.
In the daily bar chart of CYTK, below, we can see an uptrend from last July. In light of the stock market's weakness this is impressive strength. CYTK is trading above the rising 50-day moving average line and above the 200-day line which has acted as support many times in the past year.
The On-Balance-Volume (OBV) line shows a steady rise the past year and confirms the price gains as buyers of CYTK remain aggressive with more volume traded on days when CYTK has closed higher. The Moving Average Convergence Divergence (MACD) oscillator is in a bullish alignment above the zero line.